Solventum [SOLV] vs ResMed [RMD] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 21 vital metrics comparison: Solventum Corp wins in 11 metrics, ResMed Inc. wins in 9 metrics, with 0 ties. Solventum Corp appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Solventum Corp | ResMed Inc. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 7.78 | 21.69 | Solventum Corp |
| Price-to-Book Ratio | 2.37 | 5.06 | Solventum Corp |
| Debt-to-Equity Ratio | 103.94 | 13.41 | ResMed Inc. |
| PEG Ratio | 0.07 | 1.50 | Solventum Corp |
| EV/EBITDA | 14.03 | 15.51 | Solventum Corp |
| Profit Margin (TTM) | 18.69% | 27.53% | ResMed Inc. |
| Operating Margin (TTM) | 7.01% | 35.16% | ResMed Inc. |
| EBITDA Margin (TTM) | 7.01% | 35.16% | ResMed Inc. |
| Return on Equity | 38.86% | 25.68% | Solventum Corp |
| Return on Assets (TTM) | 2.94% | 14.75% | ResMed Inc. |
| Free Cash Flow (TTM) | $-10.00M | $1.65B | ResMed Inc. |
| Dividend Yield | N/A | 0.92% | N/A |
| 1-Year Return | 2.54% | -22.15% | Solventum Corp |
| Price-to-Sales Ratio (TTM) | 1.44 | 5.92 | Solventum Corp |
| Enterprise Value | $16.36B | $31.41B | ResMed Inc. |
| EV/Revenue Ratio | 1.97 | 5.82 | Solventum Corp |
| Gross Profit Margin (TTM) | 51.40% | 61.76% | ResMed Inc. |
| Revenue per Share (TTM) | $48 | $37 | Solventum Corp |
| Earnings per Share (Diluted) | $8.88 | $10.12 | ResMed Inc. |
| Beta (Stock Volatility) | 0.77 | 0.93 | Solventum Corp |
| Short % of Float | 3.65% | 9.40% | Solventum Corp |
Solventum Corp vs ResMed Inc. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Solventum Corp | 2.53% | 3.25% | 16.19% | 10.66% | -8.08% | -0.84% |
| ResMed Inc. | 1.99% | -9.53% | -10.97% | -27.81% | -25.84% | -23.83% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Solventum Corp | 2.54% | 7.76% | 7.76% | 7.76% | 7.76% | 7.76% |
| ResMed Inc. | -22.15% | -13.63% | -7.18% | 220.07% | 499.84% | 738.04% |
Performance & Financial Health Analysis: Solventum Corp vs ResMed Inc.
| Metric | SOLV | RMD |
|---|---|---|
| Market Information | ||
| Market Cap | $11.96B | $32.03B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 1,117,058 | 955,842 |
| 90 Day Avg. Volume | 1,369,466 | 1,020,554 |
| Last Close | $78.36 | $186.46 |
| 52 Week Range | $62.38 - $88.20 | $180.27 - $293.81 |
| % from 52W High | -11.16% | -36.54% |
| All-Time High | $96.05 (Mar 25, 2024) | $301.34 (Sep 06, 2021) |
| % from All-Time High | -18.42% | -38.12% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.04% | 0.11% |
| Quarterly Earnings Growth | 1.03% | 0.14% |
| Financial Health | ||
| Profit Margin (TTM) | 0.19% | 0.28% |
| Operating Margin (TTM) | 0.07% | 0.35% |
| Return on Equity (TTM) | 0.39% | 0.26% |
| Debt to Equity (MRQ) | 103.94 | 13.41 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $29.10 | $43.39 |
| Cash per Share (MRQ) | $5.06 | $9.73 |
| Operating Cash Flow (TTM) | $369.00M | $1.91B |
| Levered Free Cash Flow (TTM) | $633.25M | $1.42B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.92% |
| Last 12-Month Dividend | N/A | $2.33 |
Valuation & Enterprise Metrics Analysis: Solventum Corp vs ResMed Inc.
| Metric | SOLV (Apr 24, 2026) | RMD (Apr 26, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 7.78 | 21.69 |
| Forward P/E | 9.83 | 18.02 |
| PEG Ratio | 0.07 | 1.50 |
| Price to Sales (TTM) | 1.44 | 5.92 |
| Price to Book (MRQ) | 2.37 | 5.06 |
| Market Capitalization | ||
| Market Capitalization | $11.96B | $32.03B |
| Enterprise Value | $16.36B | $31.41B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.97 | 5.82 |
| Enterprise to EBITDA | 14.03 | 15.51 |
| Risk & Other Metrics | ||
| Beta | 0.77 | 0.93 |
| Book Value per Share (MRQ) | $29.10 | $43.39 |
Financial Statements Comparison: Solventum Corp vs ResMed Inc.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | SOLV (2025) | RMD (2025) |
|---|---|---|
| Revenue/Sales | 8.33B | 5.15B |
| Cost of Goods Sold | 3.87B | 2.09B |
| COGS % of Revenue | 46.5% | 40.6% |
| Gross Profit | 4.45B | 3.05B |
| Gross Margin | 53.5% | 59.4% |
| Research & Development | 739.00M | 331.28M |
| Operating Income (EBIT) | 632.00M | 1.69B |
| Operating Margin | 7.6% | 32.8% |
| EBITDA | 1.08B | 1.93B |
| EBITDA Margin | 13.0% | 37.4% |
| Pre-Tax Income | 1.71B | 1.68B |
| Pre-Tax Income % of Revenue | 20.6% | 32.6% |
| Income Tax | 157.00M | 276.84M |
| Income Tax % of Revenue | 1.9% | 5.4% |
| Net Income (Profit) | 1.56B | 1.40B |
| Profit Margin | 18.7% | 27.2% |
Balance Sheet & Liquidity Metrics
| Metric | SOLV (2025) | RMD (2025) |
|---|---|---|
| Cash & Equivalents | 878.00M | 1.21B |
| Total Current Assets | 3.86B | 3.51B |
| Total Current Assets % of Revenue | 46.4% | 68.1% |
| Total Current Liabilities | 3.14B | 1.02B |
| Total Current Liabilities % of Revenue | 37.7% | 19.8% |
| Long-Term Debt | 5.04B | 811.41M |
| Long-Term Debt % of Revenue | 60.5% | 15.8% |
| Total Shareholders Equity | 5.05B | 5.97B |
| Retained Earnings | 1.80B | 6.08B |
| Retained Earnings % of Revenue | 21.6% | 118.2% |
| Property, Plant & Equipment | 0 | 288.62M |
Cash Flow Statement Comparison
| Metric | SOLV (2025) | RMD (2025) |
|---|---|---|
| Operating Cash Flow | 1.82B | 1.57B |
| Operating Cash Flow % of Revenue | 21.9% | 30.5% |
| Capital Expenditures | -379.00M | -89.87M |
| Free Cash Flow | -10.00M | 1.65B |
| FCF Margin | -0.1% | 32.1% |
| Debt Repayment | -3.07B | -40.00M |
| Common Stock Repurchase | N/A | -300.03M |
Short Interest & Institutional Ownership Analysis
| Metric | SOLV | RMD |
|---|---|---|
| Shares Short | 5.38M | 11.89M |
| Short Ratio | 3.67 | 11.24 |
| Short % of Float | 3.65% | 9.40% |
| Shares Outstanding | 173.49M | 145.66M |
| Float Shares | 147.32M | 144.79M |
| % Held by Insiders | 14.99% | 0.50% |
| % Held by Institutions | 73.68% | 68.82% |
| % Held by Public | 11.33% | 30.68% |
Dividend Analysis & Yield Comparison: Solventum Corp vs ResMed Inc.
| Metric | SOLV | RMD |
|---|---|---|
| Last 12-Month Dividend | N/A | $2.33 |
| Last 12-Month Dividend Yield | N/A | 0.92% |
| 3-Year Avg Annual Dividend | N/A | $2.09 |
| 3-Year Avg Dividend Yield | N/A | 0.24% |
| 3-Year Total Dividends | N/A | $6.28 |
| Ex-Dividend Date | N/A | Feb 12, 2026 |